- Total Pro Portfolios with PHRM:
- Franklin Biotechnology Discovery A - FBDIX
- show more
- 1
- Total Do-It-Yourself Portfolios with PHRM:
- John Getrouw Portfolio 1
- akerspicks
- cecolby Portfolio 1
- EarlyBioMan
- SUPRATRADE 3007071748
- BIG MEDIUM TERM GAINS
- SUPRATRADE " BUY IT ALL NOW"!! 0408070235(august 4)
- Adizrael
- Barron's Activist Stocks 2-09-2008
- Barron's Activist Stocks 3-08-2008
- show more
- 19
- TheCompassOnline.com
- haus Portfolio 1
- petstei Portfolio 1
- Barron's Research Reports 7-9-07
- SUPRATRADE TACTICS 0108070147
- Jszymanski Portfolio 1
- RAR
- nik's healthcare portfolio
- Stock Merger Arbitrage
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:barrons2 |
Date:03 08 08 |
Money-manager Steven Cohen trimmed his position to 2.24 million shares (6%), from the 3.07 million (8.3%) he had reported owning in January. |
|
Not yet rated
Rate now:
|
|
By:barrons2 |
Date:02 09 08 |
Hedge fund S.A.C. Capital said that Celgene's (CELG) $72-a-share offer for Pharmion wouldn't "fairly compensate" shareholders, and said the drug maker could be worth $80 to $100 a share. S.A.C. Capital said Pharmion's drug, Vidaza, which is used to treat patients with higher-risk myelodysplastic syndromes, or bone-marrow diseases, could capture $100 million to $250 million more in sales than current projections, if a competitor's drug has worse survival data. S.A.C. Capital, run by billionaire investor Steve Cohen, holds 3,109,168 shares (8.3%). |
|
Not yet rated
Rate now:
|
|
By:Barrons |
Date:07 07 07 |
From Barron's 7-9-07: |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Upgraded by Matrix Research from Hold to Buy |
|
Not yet rated
Rate now:
|
|
Date:01 20 07 |
|
Looking to go to $40 |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Upgraded by Prudential from Underweight to Neutral |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |



